Abstract

Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review

J Crohns Colitis. 2020 Nov 11;jjaa227. doi: 10.1093/ecco-jcc/jjaa227. Online ahead of print.

Kate Gallagher 1, Alexandra Catesson 1, Julian L Griffin 1, Elaine Holmes 1 2, Horace R T Williams 1 3

 
     

Author information

  • 1Department of Metabolism Digestion and Reproduction, Imperial College London, United Kingdom.
  • 2Institute of Health Futures, Murdoch University, Perth, WA, Australia.
  • 3Department of Gastroenterology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

Abstract

Background and aims: The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are chronic, idiopathic gastrointestinal (GI) diseases. Whilst their precise etiology is unknown, it is thought to involve a complex interaction between genetic predisposition and an abnormal host immune response to environmental exposures, likely microbial. Microbial dysbiosis has frequently been documented in IBD. Metabolomics (the study of small molecular intermediates and end products of metabolism in biological samples) provides a unique opportunity to characterize disease-associated metabolic changes and may be of particular use in quantifying gut microbial metabolism. Numerous metabolomic studies have been undertaken in inflammatory bowel disease populations, identifying consistent alterations in a range of molecules across several biological matrices. This systematic review aims to summarize these findings.

Methods: A comprehensive, systematic search was carried out using Medline and EMBASE. All studies were reviewed by two authors independently using predefined exclusion criteria. A total of sixty-four relevant papers were quality assessed and included in the review.

Results: Consistent metabolic perturbations were identified, including increases in levels of branched chain amino acids and lipid classes across stool, serum, plasma and tissue biopsy samples, and reduced levels of microbially modified metabolites in both urine (such as hippurate) and stool (such as secondary bile acids).

Conclusions: This review provides a summary of metabolomic research in IBD to date, highlighting underlying themes of perturbed gut microbial metabolism and mammalian-microbial co-metabolism associated with disease status.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.